[NEW] Anti-Payload Antibodies: Powerful Weapons for ADC PK Study

Antibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development. Due to biotransformation, ADCs can generate various in vivo forms, potentially altering the drug-to-antibody ratio (DAR) or modifying the payload/linker. Consequently, PK assays are generally required to measure different forms of ADCs, including conjugated antibodies, total antibodies, released payload, and their respective metabolites, ensuring a comprehensive understanding of their in vivo behavior.

Sino Biological has successfully developed anti-payload antibodies which are used for analyzing the plasma/serum PK profiles, DAR values, and drug load distribution of ADC drugs. Anti-payload antibodies are used to evaluate the safety and efficacy of ADC drugs in the preclinical and clinical stages, empowering the ADC drug development process.

As a great partner for pharmaceutical industry, Sino Biological is proud to announce the launch of anti-payload mAbs FREE trial campaign. You can get anti-MMAE/MMAF mAbs freely, just contact us to apply—let's get started. Move now!

Additionally, our product line includes anti-DM1/DM4/SN-38/Dxd mAbs, currently under development, catering to the evolving needs of our clients. Reach out today to get your own trial-size and experience the reliability and quality that Sino Biological brings to the pharmaceutical industry.